|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0034809,
umls-concept:C0037274,
umls-concept:C0087111,
umls-concept:C0205314,
umls-concept:C0243192,
umls-concept:C0332237,
umls-concept:C0333348,
umls-concept:C0679622,
umls-concept:C1522168,
umls-concept:C1880022,
umls-concept:C2745896
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-10-22
|
|
pubmed:abstractText |
Glucocorticoids are highly effective in the therapy of inflammatory diseases. Their value, however, is limited by side effects. The discovery of the molecular mechanisms of the glucocorticoid receptor and the recognition that activation and repression of gene expression could be addressed separately opened the possibility of achieving improved safety profiles by the identification of ligands that predominantly induce repression. Here we report on ZK 245186, a novel, non-steroidal, low-molecular-weight, glucocorticoid receptor-selective agonist for the topical treatment of inflammatory dermatoses.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1476-5381
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
158
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1088-103
|
|
pubmed:dateRevised |
2010-10-4
|
|
pubmed:meshHeading |
pubmed-meshheading:19422381-Administration, Topical,
pubmed-meshheading:19422381-Animals,
pubmed-meshheading:19422381-Anti-Inflammatory Agents,
pubmed-meshheading:19422381-Benzofurans,
pubmed-meshheading:19422381-Drug Evaluation, Preclinical,
pubmed-meshheading:19422381-Inflammation,
pubmed-meshheading:19422381-Mice,
pubmed-meshheading:19422381-Mice, Inbred Strains,
pubmed-meshheading:19422381-Pentanols,
pubmed-meshheading:19422381-Quinolines,
pubmed-meshheading:19422381-Rats,
pubmed-meshheading:19422381-Rats, Wistar,
pubmed-meshheading:19422381-Receptors, Glucocorticoid,
pubmed-meshheading:19422381-Sensitivity and Specificity,
pubmed-meshheading:19422381-Skin,
pubmed-meshheading:19422381-Skin Diseases
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.
|
|
pubmed:affiliation |
Bayer Schering Pharma, Global Drug Discovery, Berlin, Germany. heike.schaecke@bayerhealthcare.com
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
